Literature DB >> 15613143

Optic neuritis, multiple sclerosis and human leukocyte antigen: results of a 4-year follow-up study.

A A Amirzargar1, A Tabasi, F Khosravi, A Kheradvar, N Rezaei, M Naroueynejad, B Ansaripour, B Moradi, B Nikbin.   

Abstract

In the present study the relation between human leukocyte antigen (HLA), optic neuritis (ON) and multiple sclerosis (MS) has been investigated in 56 Iranian patients (46 females and 10 males). HLA-A and -B typing by microlymphocytotoxicity method and HLA-DRB, DQA and DQB by polymerase chain reaction based on sequence specific primers method was performed for the selected patients with ON. The diagnosis of clinically defined MS (CDMS) was confirmed in 15 of them (26.7%) during their follow-up. HLA-A24 was significantly higher in ON patients, whilst A23, A26, and A30 showed a significant decrease in these patients. HLA-A10 and A26 were absent in CDMS patients and A2 and A11 were significantly decreased in ON and CDMS patients. HLA-B5, B51, B38, B27, and B35 were significantly increased in ON patients compared with control subjects. HLA-B44, B16 and B38 alleles were not present in CDMS patients. Regarding DR locus, the frequency of HLA-DRB1*15 and DRB1*04 has been increased in CDMS patients, whilst the frequency of HLA-DRB1*07 and *11 was much higher in ON patients. In DQA region, the most frequent allele in the MS patients was DQA1*0102, which was significantly higher than ON patients, and control group. The frequency of DQA1*0103 was significantly increased in both patients group. In DQB1, the frequency of DQB1*0602 increased significantly in the MS patients. In conclusion existence of common genetic basis for early manifestations of MS could be suggested.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15613143     DOI: 10.1111/j.1468-1331.2004.00901.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  7 in total

Review 1.  Evidence in practice--number 8. What is the prognosis of optic neuritis? How often does it lead to multiple sclerosis?

Authors:  Sharon Sanders; Chris Del Mar; Sarah Purdy; Annelise Spinks; Lisa Tait; Brian McAvoy
Journal:  Br J Gen Pract       Date:  2005-12       Impact factor: 5.386

2.  Distinct HLA class I and II genotypes and haplotypes are associated with multiple sclerosis in Bahrain.

Authors:  Moudi Al-Nashmi; Safa Taha; Abdel Halim Salem; Isa Alsharoqi; Moiz Bakhiet
Journal:  Biomed Rep       Date:  2018-10-24

Review 3.  New directions in optic neuritis and multiple sclerosis.

Authors:  Molly E Gilbert; Robert C Sergott
Journal:  Curr Neurol Neurosci Rep       Date:  2007-05       Impact factor: 5.081

4.  The relationship between HLA-DRB1 alleles and optic neuritis in Irish patients and the risk of developing multiple sclerosis.

Authors:  Ismail Tuwir; Ciaran Dunne; John Crowley; Tarik Saddik; Ray Murphy; Lorraine Cassidy
Journal:  Br J Ophthalmol       Date:  2007-10       Impact factor: 4.638

5.  IL-2, IFN-gamma, and IL-12 gene polymorphisms and susceptibility to multiple sclerosis.

Authors:  Mohammad Ali Shokrgozar; Sheila Sarial; Aliakbar Amirzargar; Fazel Shokri; Nima Rezaei; Zohreh Arjang; Jalaledin Radfar; Manijeh Yousefi-Behzadi; Mohammad Ali Sahraian; Jamshid Lotfi
Journal:  J Clin Immunol       Date:  2009-06-20       Impact factor: 8.317

6.  Neuromyelitis optica is an HLA associated disease different from Multiple Sclerosis: a systematic review with meta-analysis.

Authors:  Marcos Papais Alvarenga; Luciana Ferreira do Carmo; Claudia Cristina Ferreira Vasconcelos; Marina Papais Alvarenga; Helcio Alvarenga-Filho; Cleonice Alves de Melo Bento; Carmen Lucia Antão Paiva; Laura Leyva-Fernández; Óscar Fernández; Regina Maria Papais-Alvarenga
Journal:  Sci Rep       Date:  2021-01-08       Impact factor: 4.379

Review 7.  Association of infections with multiple sclerosis in Gulf Cooperation Council countries: a review.

Authors:  O Al Wutayd
Journal:  J Int Med Res       Date:  2019-12-27       Impact factor: 1.671

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.